On Monday, Arcus Biosciences Inc (NYSE: RCUS) was 13.97% up from the session before settling in for the closing price of $14.6. A 52-week range for RCUS has been $6.50 – $18.98.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -10.20%. When this article was written, the company’s average yearly earnings per share was at -17.15%. With a float of $65.32 million, this company’s outstanding shares have now reached $106.40 million.
The extent of productivity of a business whose workforce counts for 627 workers is very important to gauge.
Arcus Biosciences Inc (RCUS) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arcus Biosciences Inc stocks. The insider ownership of Arcus Biosciences Inc is 38.63%, while institutional ownership is 62.53%. The most recent insider transaction that took place on Oct 08 ’25, was worth 568,611. In this transaction Chief Operating Officer of this company sold 37,792 shares at a rate of $15.05, taking the stock ownership to the 214,232 shares. Before that another transaction happened on Oct 06 ’25, when Company’s Chief Operating Officer sold 12,500 for $14.54, making the entire transaction worth $181,801. This insider now owns 214,232 shares in total.
Arcus Biosciences Inc (RCUS) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -1 earnings per share (EPS) during the time that was better than consensus figure (set at -1.07) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -17.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.77% during the next five years compared to -10.20% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
You can see what Arcus Biosciences Inc (RCUS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.17, a number that is poised to hit -1.31 in the next quarter and is forecasted to reach -4.21 in one year’s time.
